Evidence for an oncogenic modifier role for mutant histone acetyltransferases in diffuse large B-cell lymphoma

References

• Morton LM, Wang SS, Devesa SS, et al. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood. 2006;107:265–276.
   PubMed Web of Science ®Google Scholar
• Cerchietti LC, Hatzi K, Caldas-Lopes E, et al. BCL6 repression of EP300 in human diffuse large B cell lymphoma cells provides a basis for rational combinatorial therapy. J Clin Invest. 2010;120:4569–4582.
   PubMed Web of Science ®Google Scholar
• Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403:503–511.
   PubMed Web of Science ®Google Scholar
• Pasqualucci L, Dominguez-Sola D, Chiarenza A, et al. Inactivating mutations of acetyltransferase genes in B-cell lymphoma. Nature. 2011;471:189–195.
   PubMed Web of Science ®Google Scholar
• Pasqualucci L, Trifonov V, Fabbri G, et al. Analysis of the coding genome of diffuse large B-cell lymphoma. Nat Genet. 2011;43:830–837.
   PubMed Web of Science ®Google Scholar
• Morin RD, Mendez-Lago M, Mungall AJ, et al. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature. 2011;476:298–303.
   PubMed Web of Science ®Google Scholar
• Lohr JG, Stojanov P, Lawrence MS, et al. Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing. Proc Natl Acad Sci USA. 2012;109:3879–3884.
   PubMed Web of Science ®Google Scholar
• Morin RD, Mungall K, Pleasance E, et al. Mutational and structural analysis of diffuse large B-cell lymphoma using whole-genome sequencing. Blood. 2013;122:1256–1265.
   PubMed Web of Science ®Google Scholar
• Haery L, Thompson RC, Gilmore TD. Histone acetyltransferases and histone deacetylases in B- and T-cell development, physiology and malignancy. Genes Cancer. 2015;6:184–213.
   PubMedGoogle Scholar
• Pasqualucci L, Khiabanian H, Fangazio M, et al. Genetics of follicular lymphoma transformation. Cell Rep. 2014;6:130–140.
   PubMed Web of Science ®Google Scholar
• Garbati MR, Alço G, Gilmore TD. Histone acetyltransferase p300 is a coactivator for transcription factor REL and is C-terminally truncated in the human diffuse large B-cell lymphoma cell line RC-K8. Cancer Lett. 2010;291:237–245.
   PubMed Web of Science ®Google Scholar
• Haery L, Lugo-Pico JG, Henry RA, et al. Histone acetyltransferase-deficient p300 mutants in diffuse large B cell lymphoma have altered transcriptional regulatory activities and are required for optimal cell growth. Mol Cancer. 2014;13:29.
   PubMed Web of Science ®Google Scholar
• Garbati MR, Thompson RC, Haery L, et al. A rearranged EP300 gene in the human B-cell lymphoma cell line RC-K8 encodes a disabled transcriptional co-activator that contributes to cell growth and oncogenicity. Cancer Lett. 2011;302:76–83.
   PubMed Web of Science ®Google Scholar
• Sambrook J, Fritsch EF, Maniatis T. Molecular cloning: a laboratory manual. 2nd ed. Cold Spring Harbor (NY): Cold Spring Harbor Laboratory Press; 1989.
   Google Scholar
• Starczynowski DT, Reynolds JG, Gilmore TD. Mutations of tumor necrosis factor alpha-responsive serine residues within the C-terminal transactivation domain of human transcription factor REL enhance its in vitro transforming ability. Oncogene. 2005;24:7355–7368.
   PubMed Web of Science ®Google Scholar
• Liang MC, Bardhan S, Porco JA Jr, et al. The synthetic epoxyquinoids jesterone dimer and epoxyquinone A monomer induce apoptosis and inhibit REL (human c-Rel) DNA binding in an IkappaBalpha-deficient diffuse large B-cell lymphoma cell line. Cancer Lett. 2006;241:69–78.
   PubMed Web of Science ®Google Scholar
• Rasband WS. ImageJ. 1997–2012. Available from: http://imagej.nih.gov/ij/.
   Google Scholar
• Yeo AT, Chennamadhavuni S, Whitty A, et al. Inhibition of oncogenic transcription factor REL by the natural product derivative calafianin monomer 101 induces proliferation arrest and apoptosis in human B-lymphoma cell lines. Molecules. 2015;20:7474–7494.
   PubMed Web of Science ®Google Scholar
• Huang HC, Sundseth R, Hansen U. Transcription factor LSF binds two variant bipartite sites within the SV40 late promoter. Genes Dev. 1990;4:287–298.
   PubMed Web of Science ®Google Scholar
• Jain S, Wei J, Mitrani LR, et al. Auto-acetylation stabilizes p300 in cardiac myocytes during acute oxidative stress, promoting STAT3 accumulation and cell survival. Breast Cancer Res Treat. 2012;135:103–114.
   PubMed Web of Science ®Google Scholar
• Kalaitzidis D, Davis RE, Rosenwald A, et al. The human B-cell lymphoma cell line RC-K8 has multiple genetic alterations that dysregulate the Rel/NF-kappaB signal transduction pathway. Oncogene. 2002;21:8759–8768.
   PubMed Web of Science ®Google Scholar
• Collart MA, Baeuerle P, Vassalli P. Regulation of tumor necrosis factor alpha transcription in macrophages: involvement of four kappa B-like motifs and of constitutive and inducible forms of NF-kappa B. Mol Cell Biol. 1990;10:1498–1506.
   PubMed Web of Science ®Google Scholar
• Hiscott J, Marois J, Garoufalis J, et al. Characterization of a functional NF-kappa B site in the human interleukin 1 beta promoter: evidence for a positive autoregulatory loop . Mol Cell Biol. 1993;13:6231–6240.
   PubMed Web of Science ®Google Scholar
• Kirch HC, Flaswinkel S, Rumpf H, et al. Expression of human p53 requires synergistic activation of transcription from the p53 promoter by AP-1, NF-kappaB and Myc/Max. Oncogene. 1999;18:2728–2738.
   PubMed Web of Science ®Google Scholar
• Jacque E, Billot K, Authier H, et al. RelB inhibits cell proliferation and tumor growth through p53 transcriptional activation. Oncogene. 2013;32:2661–2669.
   PubMed Web of Science ®Google Scholar
• Kallwellis K, Grempler R, Gunther S, et al. Tumor necrosis factor alpha induces the expression of the nuclear protein p8 via a novel NF kappaB binding site within the promoter. Horm Metab Res. 2006;38:570–574.
   PubMed Web of Science ®Google Scholar
• Delmore JE, Issa GC, Lemieux ME, et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell. 2011;146:904–917.
   PubMed Web of Science ®Google Scholar
• Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA. 2005;102:15545–15550.
   PubMed Web of Science ®Google Scholar
• Subramanian A, Kuehn H, Gould J, et al. GSEA-P: a desktop application for Gene Set Enrichment Analysis. Bioinformatics. 2007;23:3251–3253.
   PubMed Web of Science ®Google Scholar
• Starczynowski DT, Reynolds JG, Gilmore TD. Deletion of either C-terminal transactivation subdomain enhances the in vitro transforming activity of human transcription factor REL in chicken spleen cells. Oncogene. 2003;22:6928–6936.
   PubMed Web of Science ®Google Scholar
• Kalaitzidis D, Gilmore TD. Genomic organization and expression of the rearranged REL proto-oncogene in the human B-cell lymphoma cell line RC-K8. Genes Chromosomes Cancer. 2002;34:129–135.
   PubMed Web of Science ®Google Scholar
• Levens D. You don’t muck with MYC. Genes Cancer. 2010;1:547–554.
   PubMedGoogle Scholar
• Barretina J, Caponigro G, Stransky N, et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 2012;483:603–607.
   PubMed Web of Science ®Google Scholar
• Kalaitzidis D. Characterization of the mis-regulated Rel/NF-kappaB pathway in the RC-K8 human lymphoma cell line and characterization of a conditionally active REL-estrogen receptor fusion protein [PhD Dissertation]. Boston (MA): Boston University 2006.
   Google Scholar
• Compagno M, Lim WK, Grunn A, et al. Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma. Nature. 2009;459:717–721.
   PubMed Web of Science ®Google Scholar
• Lu D, Thompson JD, Gorski GK, et al. Alterations at the Rel locus in human lymphoma. Oncogene. 1991;6:1235–1241.
   PubMed Web of Science ®Google Scholar
• Bash J, Zong WX, Gélinas C. c-Rel arrests the proliferation of HeLa cells and affects critical regulators of the G1/S-phase transition. Mol Cell Biol. 1997;17:6526–6536.
   PubMed Web of Science ®Google Scholar
• Schwartz RC, Witte ON. A recombinant murine retrovirus expressing v-Rel is cytopathic. Virology. 1988;165:182–190.
   PubMed Web of Science ®Google Scholar
• Gilmore TD, Gélinas C. Methods for assessing the in vitro transforming activity of NF-κB transcription factor c-Rel and related proteins. Methods Mol Biol. 2015;1280:427–446.
   PubMedGoogle Scholar
• Chin M, Herscovitch M, Zhang N, et al. Overexpression of an activated REL mutant enhances the transformed state of the human B-lymphoma BJAB cell line and alters its gene expression profile. Oncogene. 2009;28:2100–2111.
   PubMed Web of Science ®Google Scholar
• Richardson PM, Gilmore TD. vRel is an inactive member of the Rel family of transcriptional activating proteins. J Virol. 1991;65:3122–3130.
   PubMed Web of Science ®Google Scholar
• Gilmore TD. Multiple mutations contribute to the oncogenicity of the retroviral oncoprotein v-Rel. Oncogene. 1999;18:6925–6937.
   PubMed Web of Science ®Google Scholar
• Boi M, Gaudio E, Bonetti P, et al. The BET bromodomain inhibitor OTX015 affects pathogenetic pathways in preclinical B-cell tumor models and synergizes with targeted drugs. Clin Cancer Res. 2015;21:1628–1638.
   PubMed Web of Science ®Google Scholar
• Maestro R, Dolcetti R, Gasparotto D, et al. High frequency of p53 gene alterations associated with protein overexpression in human squamous cell carcinoma of the larynx. Oncogene. 1992;7:1159–1166.
   PubMed Web of Science ®Google Scholar
• Oren M, Rotter V. Mutant p53 gain-of-function in cancer. Cold Spring Harb Perspect Biol. 2010;2:a001107.
   PubMed Web of Science ®Google Scholar
• Muller PA, Vousden KH. p53 mutations in cancer. Nat Cell Biol. 2013;15:2–8.
   PubMed Web of Science ®Google Scholar
• Cerchietti L, Leonard JP. Targeting the epigenome and other new strategies in diffuse large B-cell lymphoma: beyond R-CHOP. Hematology Am Soc Hematol Educ Program. 2013;2013:591–595.
   PubMedGoogle Scholar